Thimble Point Acquisition and Pear Therapeutics today announced an additional commitment from an affiliate of Thimble Point’s sponsor of up to $50 million to support the companies’ planned merger.
The commitment is in addition to the $23 million that the affiliate of Thimble Point’s sponsor made as part of the PIPE, raising the total to $175 million. In connection with the revised definitive agreements, Pear has agreed to waive the requirement that total cash proceeds equal or exceed $200 million.
The SPAC had also raised $276 million in a February IPO.
A shareholder vote on the deal is set for Nov. 30.
Pear develops prescription digital therapeutics (PDTs), which are software applications designed to collect real world data for use by prescribing clinicians and by payors and health systems for population health management. Read more.
